Apr 1, 2012
By:
William Looney
Patents are the chief incentive for drug development. Industry should educate stakeholders about IP protection as a crucial driver of innovation, before it's too late.
|
|
Mar 12, 2012
By:
William Looney
With growth as its guiding light, Novartis has big plans for the emerging markets. Pharm Exec sits down with CEO Joe Jimenez to understand what it will take the company to best the competition.
|
Mar 1, 2012
By:
William Looney
Pharm Exec's latest EAB meeting offered a frank exchange on this magazine's digital future.
|
|
Feb 1, 2012
By:
William Looney
A new generation of products for inflammatory disease is coming forward, promising better promise and possibly a cure.
|
|
Jan 1, 2012
By:
William Looney
The challenge for 2012 is that many new treatments may not complete the move from 'bench to bedside' in time to plug the yawning revenue gap.
|
|
Dec 1, 2011
By:
William Looney
Pharm Exec sits down with CEO Atsushi Nagahisa to explore how culture can maximize the value of an inherited portfolio
|
|
Dec 1, 2011
By:
William Looney
Keeping skittish patients on their medicines ought to be a strategic priority for Big Pharma — but is it? Pharm Exec convenes an expert round table to examine how best to make progress and agree on some practical steps for incorporation in the campaign agenda.
|
|
Dec 1, 2011
By:
William Looney
The gap in perception is one of industry's biggest problems because it adds ballast to the idea that medicines are just a simple procurement item, writes William Looney.
|
Nov 1, 2011
By:
William Looney
If high prices that lower access are attributable to a flawed R&D model, can industry embrace delivering better results at lower costs.
|
|
PharmExec Blog
Follow Us
RSS
Bookstore
